Trial Profile

Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Select Low-grade Lymphomas

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eiletoclax (Primary)
Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
Focus Adverse reactions; First in man
Sponsors Eilean Therapeutics

Most Recent Events

25 Jul 2025 Status changed from not yet recruiting to recruiting.
01 Feb 2024 New trial record
29 Jan 2024 According to an EILEAN THERAPEUTICS media release, the Human Research Ethics Committee in Australia has given clearance to begin this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com